PT91371A - Processo para a preparacao de conjugados de medicamentos citotoxicos, nomeadamente conjugados de medicamentos de metotrexato - Google Patents

Processo para a preparacao de conjugados de medicamentos citotoxicos, nomeadamente conjugados de medicamentos de metotrexato

Info

Publication number
PT91371A
PT91371A PT91371A PT9137189A PT91371A PT 91371 A PT91371 A PT 91371A PT 91371 A PT91371 A PT 91371A PT 9137189 A PT9137189 A PT 9137189A PT 91371 A PT91371 A PT 91371A
Authority
PT
Portugal
Prior art keywords
medicines
metotrexate
conjugates
preparation
cytotoxic
Prior art date
Application number
PT91371A
Other languages
English (en)
Other versions
PT91371B (pt
Inventor
David Arthur Johnson
Bennett Coleman Laguzza
William Leonard Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT91371A publication Critical patent/PT91371A/pt
Publication of PT91371B publication Critical patent/PT91371B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PT91371A 1988-08-08 1989-08-03 Processo para a preparacao de conjugados de medicamentos citotoxicos, nomeadamente conjugados de medicamentos de metotrexato PT91371B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/229,941 US5028697A (en) 1988-08-08 1988-08-08 Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers

Publications (2)

Publication Number Publication Date
PT91371A true PT91371A (pt) 1990-03-08
PT91371B PT91371B (pt) 1995-05-04

Family

ID=22863313

Family Applications (1)

Application Number Title Priority Date Filing Date
PT91371A PT91371B (pt) 1988-08-08 1989-08-03 Processo para a preparacao de conjugados de medicamentos citotoxicos, nomeadamente conjugados de medicamentos de metotrexato

Country Status (14)

Country Link
US (1) US5028697A (pt)
EP (1) EP0354729B1 (pt)
JP (1) JPH02256700A (pt)
KR (1) KR900002803A (pt)
CN (1) CN1040204A (pt)
AU (1) AU619328B2 (pt)
DE (1) DE68912232T2 (pt)
DK (1) DK382889A (pt)
HU (1) HU208161B (pt)
IL (1) IL91181A0 (pt)
MX (1) MX165003B (pt)
NZ (1) NZ230199A (pt)
PT (1) PT91371B (pt)
ZA (1) ZA895909B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5556623A (en) * 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
JPH072895A (ja) * 1993-04-28 1995-01-06 Eli Lilly & Co 抗体−薬物複合体
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
JP2004536027A (ja) 2000-12-01 2004-12-02 ジョーンズ・ホプキンス・ユニーバーシティー グリコシル化／ガラクトシル化ペプチドの接合体、二官能性リンカー、およびヌクレオチドのモノマー／ポリマー、および関連する組成物および使用方法
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US9221867B2 (en) * 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP2360258B1 (en) * 2005-02-18 2014-10-08 Angiochem Inc. Aprotinin polypeptides for transporting a compound across the blood-brain barrier
ES2424242T3 (es) 2005-07-15 2013-09-30 Angiochem Inc. Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
CN101355952B (zh) 2005-11-28 2012-03-21 韦罗制药有限公司 用于减少肾毒性的组合物及其使用方法
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2188311B1 (en) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
JP5504179B2 (ja) 2008-03-03 2014-05-28 トスク インコーポレーティッド 毒性を低減するためのメトトレキセートアジュバントおよびその使用法
CA2721019C (en) * 2008-04-18 2015-09-15 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
US8828925B2 (en) 2008-10-15 2014-09-09 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
MX2011004017A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de agonistas glp-1 y usos de los mismos.
CA2745524C (en) * 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
JP2012512185A (ja) 2008-12-17 2012-05-31 アンジオケム インコーポレーテッド 膜１型マトリックス金属タンパク質阻害剤およびその使用
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
IN2012DN00248A (pt) 2009-07-02 2015-05-01 Angiochem Inc
CN109620830A (zh) 2011-05-16 2019-04-16 建新公司 使用甲氨蝶呤诱导免疫耐受性
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
HUE057768T2 (hu) 2014-09-17 2022-06-28 Zymeworks Inc Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
AU8762982A (en) * 1981-07-02 1983-02-02 Walton, A.G. Glycosaminoglycan drug complexes
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3482444D1 (de) * 1983-03-30 1990-07-19 Lilly Industries Ltd Immunoglobulinkonjugate.
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
DE3788058T2 (de) * 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
US4918165A (en) * 1987-07-16 1990-04-17 Ophthalmic Research Corporation Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction

Also Published As

Publication number Publication date
NZ230199A (en) 1991-09-25
MX165003B (es) 1992-10-13
JPH02256700A (ja) 1990-10-17
EP0354729B1 (en) 1994-01-12
US5028697A (en) 1991-07-02
HUT50850A (en) 1990-03-28
KR900002803A (ko) 1990-03-23
ZA895909B (en) 1991-04-24
DE68912232D1 (de) 1994-02-24
DE68912232T2 (de) 1994-05-19
AU3933889A (en) 1990-02-08
IL91181A0 (en) 1990-03-19
EP0354729A3 (en) 1991-04-17
PT91371B (pt) 1995-05-04
DK382889D0 (da) 1989-08-04
DK382889A (da) 1990-02-09
CN1040204A (zh) 1990-03-07
AU619328B2 (en) 1992-01-23
HU208161B (en) 1993-08-30
EP0354729A2 (en) 1990-02-14

Similar Documents

Publication Publication Date Title
PT91371A (pt) Processo para a preparacao de conjugados de medicamentos citotoxicos, nomeadamente conjugados de medicamentos de metotrexato
MX164971B (es) Procedimiento para la preparacion de conjugados de medicamentos citoxicos
BR8902297A (pt) Processo para a preparacao de 1,1,1,2-tetrafluoretano
IT8820145A0 (it) Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
NO903001L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater med forlenget frigivelse.
PT89705A (pt) Processo para a preparacao de 2', 3'-didesoxi-2', 2'-difluoronucleosidos
BR9003345A (pt) Processo para a preparacao de 1,1,1,2-tetrafluoretano
PT92213A (pt) Processo para a preparacao de conjugados de anticorpo-droga
PT89779A (pt) Processo para a preparacao de derivados da piperidina
PT89922A (pt) Processo para a preparacao de derivados da tiazolidenodiona
PT89545A (pt) Processo para a preparacao de derivados da isoquinolinona
PT90914A (pt) Processo para a preparacao de derivados de benzazepinae benzotiazapina
DZ1618A1 (fr) Procédé de préparation de distilmats moyens.
PT92539A (pt) Processo para a preparacao de derivados de anfotericina b
IT1205834B (it) Derivati tiodiossolanici ad attivita' mucolitica a procedimento per la loro preparazione
PT93736A (pt) Processo para a preparacao de n,n'-ditrimetoxi-benzoil-piperazinas 2- substituidas
GB2228922B (en) Packaging drugs
BR9003346A (pt) Processo para a preparacao de 1,2-dicloro-1,1,2-trifluoretano
FI913845A0 (fi) Farmaceutiskt preparat foer behandling av tonsillitis.
EP0299057A4 (en) INCREASING THE POWER OF CYTOTOXIC CONJUGATES.
BR9004116A (pt) Processo para a preparacao de n,n'-bis-1,3,5-triazin-6-il-piperazinas
PH25607A (en) Benzenesulfonamide derivatives, a process for the preparation thereof
PT90082A (pt) Processo para a preparacao de pirroles dissubstituidos
IE892534L (en) Cytotoxic drug conjugates
IE892533L (en) Cytotoxic drug conjugates

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19941010

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19960430